Deep sequencing and integrative genome analysis: Approaching a new class of biomarkers and therapeutic targets for breast cancer

Pharmacogenomics

Volumn 14, Issue 1, 2013, Pages 5-8

  Zografos, George ^a   Liakakos, Theodore ^a   Roukos, Dimitrios H ^b,c  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

biomarkers; breast cancer; copy number changes; gene expression; heterogeneity; mutations; transcriptome

Indexed keywords

AROMATASE INHIBITOR; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CORE BINDING FACTOR BETA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; TRANSCRIPTION FACTOR RUNX1; TRASTUZUMAB;

ADJUVANT THERAPY; AKT3 GENE; BREAST CANCER; BREAST CARCINOMA; CANCER SURVIVAL; CBFB GENE; CHROMATIN IMMUNOPRECIPITATION; COPY NUMBER VARIATION; DRUG RESPONSE; DRUG TARGETING; EXOME; GENE; GENE EXPRESSION PROFILING; GENE MAPPING; GENETIC ANALYSIS; GENETIC HETEROGENEITY; HIGH THROUGHPUT SEQUENCING; HUMAN; INDIVIDUALIZATION; MAGI3 GENE; MEDICAL DECISION MAKING; MUTATIONAL ANALYSIS; ONCOGENE NEU; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; PREDICTION; RECEPTOR BINDING; REVIEW; RNA SEQUENCE; RUNX1 GENE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FEMALE; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871435103     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.189     Document Type: Review

References (20)

1. Stephens PJ, Tarpey PS, Davies H et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486(7403), 400-404 (2012).
2. Shah SP, Roth A, Goya R et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486(7403), 395-399 (2012).
3. Banerji S, Cibulskis K, Rangel-Escareno C et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486(7403), 405-409 (2012).
4. Ellis MJ, Ding L, Shen D et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486(7403), 353-360 (2012).
5. Curtis C, Shah SP, Chin SF et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403), 346-352 (2012).
6. Ross-Innes CS, Stark R, Teschendorff AE et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481(7381), 389-393 (2012).
7. Feero WG, Guttmacher AE, Collins FS. Genomic medicine-an updated primer. N. Engl. J. Med. 362(21), 2001-2011 (2010).
8. Roukos DH. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J. 11(2), 81-92 (2011).
9. Roukos DH. Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark. Med. 4(4), 583-586 (2010).
10. Roukos DH. Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev. Med. Devices 7(6), 723-726 (2010).
11. Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat. Med. 17, 297-303 (2011).
12. Roukos DH. Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11(8), 1039-1043 (2010).
13. Ecker JR, Bickmore WA, Barroso I, Pritchard JK, Gilad Y, Segal E. Genomics: ENCODE explained. Nature 489(7414), 52-55 (2012).
14. ENCODE Project Consortium, Bernstein BE, Birney E et al. An integrated encyclopedia of DNA elements in the human genome. Nature 489(7414), 57-74 (2012).
15. Blaxter M. Genetics. Revealing the dark matter of the genome. Science 330(6012), 1758-1759 (2010).
16. Khatri P, Sirota M, Butte AJ. Ten years of pathway analysis: current approaches and outstanding challenges. PLoS Comput. Biol. 8(2), e1002375 (2012).
17. Ideker T, Krogan NJ. Differential network biology. Mol. Syst. Biol. 8, 565 (2012).
18. Califano A, Butte AJ, Friend S, Ideker T, Schadt E. Leveraging models of cell regulation and GWAS data in integrative network-based association studies. Nat. Genet. 44(8), 841-847 (2012).
19. Roukos DH. Cancer genome explosion and systems biology: impact on surgical oncology? Ann. Surg. Oncol. 18(1), 12-15 (2011).
20. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 12, 56-68 (2011).